Bernard L, Lecomte B, Pereira B, Proux A, Boyer A, Sautou V
Pôle pharmacie, CHU de Clermont-Ferrand, 63003 Clermont-Ferrand, France.
Pôle pédiatrie, pharmacie, CHU de Clermont-Ferrand, 63003 Clermont-Ferrand, France.
Arch Pediatr. 2015 Feb;22(2):146-53. doi: 10.1016/j.arcped.2014.11.015. Epub 2014 Dec 20.
Palivizumab, a humanized monoclonal antibody directed against respiratory syncytial virus (RSV), is the only existent immunoprophylaxis therapy for prevention of serious lower respiratory tract disease caused by RSV in infants (up to 2 years of age), particularly in those who meet high-risk criteria (preterm infants and/or those with bronchopulmonary or congenital heart disease). In our region, the monthly injections are not given at the hospital but by private pediatricians during the epidemic season. We aimed to assess the influence of an educational and personalized support of preterm infants treated with Palivizumab on patient compliance during the last season.
A three-level educational intervention was conducted: the parents were advised in the neonatology units, then at the hospital pharmacy where the treatment was delivered, and finally by their referent pediatrician. We evaluated the impact of this intervention by measuring patient compliance, defined by two criteria, and by measuring the rate of rehospitalization for RSV bronchiolitis. We compared these results to those of the previous season (2011-2012) in which no interventional program was conducted.
Compliance was better in the group of patients followed (2012-2013); 59.7% of them received all the palivizumab doses, while only 32.9% of the infants not followed received all doses. The number of injections given at appropriate intervals remained stable between the two groups and no significant difference was found in the rate of RSV bronchiolitis rehospitalizations.
This educational intervention program, coordinated by doctors and pharmacists, is associated with improved treatment compliance in high-risk of RSV bronchiolitis infants. To optimize such a care program, we have planned to set up and then evaluate a call center procedure involving extensive counseling for parents and reminder telephone calls.
帕利珠单抗是一种针对呼吸道合胞病毒(RSV)的人源化单克隆抗体,是目前唯一可用于预防婴儿(2岁以下)由RSV引起的严重下呼吸道疾病的免疫预防疗法,尤其适用于符合高危标准的婴儿(早产儿和/或患有支气管肺疾病或先天性心脏病的婴儿)。在我们地区,每月的注射并非在医院进行,而是在流行季节由私人儿科医生进行。我们旨在评估对接受帕利珠单抗治疗的早产儿进行教育和个性化支持对上个季节患者依从性的影响。
实施了三级教育干预:在新生儿科对家长进行指导,然后在提供治疗的医院药房进行指导,最后由负责的儿科医生进行指导。我们通过测量依从性(由两个标准定义)以及测量RSV细支气管炎的再次住院率来评估该干预措施的影响。我们将这些结果与上一个季节(2011 - 2012年)未实施干预项目的结果进行了比较。
接受随访的患者组(2012 - 2013年)依从性更好;其中59.7%的患者接受了所有剂量的帕利珠单抗,而未接受随访的婴儿中只有32.9%接受了所有剂量。两组之间按适当间隔进行的注射次数保持稳定,并且在RSV细支气管炎再次住院率方面未发现显著差异。
由医生和药剂师协调的这一教育干预项目与改善RSV细支气管炎高危婴儿的治疗依从性相关。为了优化这样的护理项目,我们计划建立并评估一个呼叫中心程序,该程序包括为家长提供广泛咨询和提醒电话。